Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)

Chest

Volumn 133, Issue 6 SUPPL. 6, 2008, Pages 670S-707S

  Harrington, Robert A ^a,b   Becker, Richard C ^b   Cannon, Christopher P ^c   Gutterman, David ^d   Lincoff, A Michael ^e   Popma, Jeffrey J ^c   Steg, Gabriel ^f   Guyatt, Gordon H ^g   Goodman, Shaun G ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BICHAT HOSPITAL   (France)

^g MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^h ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Acute coronary syndromes; Anticoagulants; Antiplatelet therapies; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DALTEPARIN; DESULFATOHIRUDIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PRASUGREL; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD TOXICITY; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMOLYTIC UREMIC SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HEMORRHAGE; ISCHEMIA; LIVER FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE CORONARY SYNDROME; ASPIRIN; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TYROSINE;

EID: 45949090749     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0691     Document Type: Article

References (163)

1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897-902
2. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343:311-322
3. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335:775-782
4. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281:707-713
5. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina): ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002 [summary article]; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106:1893-1900
6. Bertrand ME, Simoons ML, Fox KA, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23:1809-1840
7. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101:1206-1218
8. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002; 324:71-86
9. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of Veterans Administration Cooperative Study. N Engl J Med 1983; 309:396-403
10. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both, in unstable angina: results of a Canadian multicentre clinical trial. N Engl J Med 1985; 313:1369-1375
11. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111
12. RISC Group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 335:827-830
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996; 348:1329-1339
14. Kong DF, Hasselblad V, Kandzari DE, et al. Seeking the optimal aspirin dose in acute coronary syndromes. Am J Cardiol 2002; 90:622-625
15. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
16. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496-501
17. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994; 331:489-495
18. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 996; 334:1084-1089
19. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671
20. Moy B, Wang JC, Raffel GD, et al. Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med 2000; 160:1370-1372
21. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773-1777
22. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999; 34:1891-1894
23. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99:2364-2366
24. Mishkel GJ, Aguirre FV, Ligon RW, et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999; 34:1884-1890
25. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39:9-14
26. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624-629
27. Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101:590-593
28. Berger PB, Mahaffey KW, Meier SJ, et al. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J 2002; 143:841-846
29. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111:3366-3373
30. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCT-CURE study. Lancet 2001; 358:527-533
31. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420
32. Steinhubl S, Darrah S, Brennan D, et al. Optimal duration of pretreatment with clopidogrel prior to PCI: data from the CREDO trial [abstract]. Circulation 2003; 108(suppl IV): 374
33. Seyfarth HJ, Koksch M, Roethig C, et al. Effect of 300- and 450-ing clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143:118-123
34. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232-238
35. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48:931-938
36. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531-1538
37. Weintraub WS, Mahoney EM, Larny A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005; 45:838-845
38. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189-198
39. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100:2045-2048
40. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349:1429-1435
41. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497
42. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina; receptor suppression using integrilin therapy. N Engl J Med 1998; 339:436-443
43. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007; 297:591-602
44. Giugliano RP, Newby LK, Harrington RA, et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome; study design and rationale. Am Heart J 2005; 149:994-1002
45. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961
46. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:1689-1696
47. EPISTENT Investigators. Randomised placebo-controlled ami balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: evaluation of platelet IIb/IIIa inhibitor for stent-ing. Lancet 1998; 352:87-92
48. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months; the EPIC Investigators. Lancet 1994; 343:881-886
49. Marso SP, Lincoff AM, Ellis SC, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999; 100:2477-2484
50. ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999; 100:799-806
51. Mathew V, Grill DE, Scott CG, et al. The influence of abciximab use on clinical outcome after aortoeoronary vein graft interventions. J Am Coll Cardiol 1999; 34:1163-1169
52. Muhlestein JB, Karagounis LA, Treehan S, et al. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997; 30:1729-1734
53. Kong DF, Hasselblad V, Harrington RA, et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003; 92:651-655
54. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357:1915-1924
55. IMPACT-II. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: Integrum to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349:1422-1428
56. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrum Therapy: novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT); a randomised, placebo-controlled trial. Lancet 2000; 356:2037-2044
57. O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287:618-621
58. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: the PURSUIT trial experience. Circulation 1999; 99:2892-2900
59. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-1505
60. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497
61. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96:1445-1453
62. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894
63. Simon DI, Liu CB, Ganz P, et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv 2001; 52:425-432
64. Suffer D, Moussa I, Karatepe M, et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol 2003; 91:872-875
65. Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89:647-650
66. Batchelor WB, Tolleson TR, Huang Y, et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial; comparison of measurements of platelet aggregation with aggrastat, reopro, and eptifibatide. Circulation 2002; 106:1470-1476
67. Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002; 90:1421-1423
68. Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002; 105:316-321
69. Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 2001; 103:2891-2896
70. Fox KA, Poole-Wilson PA, Henderson RA, et al. Randomized Intervention Trial of unstable Angina Investigators: interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction; the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360:743-751
71. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: gradient of benefit related to the revascularization strategy. Eur Heart J 2002; 23:1441-1448
72. Mehta RH, Chen AY, Pollack CV Jr, et al. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2006; 98:624-627
73. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: re-sults from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292:2096-2104
74. Tricoci P, Peterson ED, Mulgund J, et al. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol 2006; 98:1172-1176
75. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292:1555-1562
76. Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46:1490-1495
77. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774-782
78. Hill SR, Carless PA, Henry DA, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews 2000; CD002042
79. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96:1200-1206
80. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294:3108-3116
81. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000; 101:366-571
82. Cohen M, Adams PC, Hawkins L, et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol 1990; 66:1287-1292
83. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial; Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89:81-88
84. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: the RISC Group. Lancet 1990; 336:327-330
85. Basu D, Galluis A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287:324-327
86. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315:1109-1114
87. Turpie AGG, Robinson JB, Doyle DJ, et al. Comparison of high dose with low dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989; 320:353-357
88. Hsia J, Kleiman N, Aquire F, et al. Heparin-induced prolongation of partial thromboplastin time and thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 1992; 20:31-35
89. Becker RC, Cannon CP, Tracy RP, et al. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and inhospital clinical events in unstable angina and non-Q wave myocardial infarction. Am Heart J 1996; 131:421-433
90. Lee MS, Wali AU, Menon V, et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002; 14:91-101
91. Hassan WM, Flaker GC, Feutz G, et al. Improved anticoagulation with a weight adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. J Thromb Thrombolysis 1995; 2:245-249
92. Becker RC, Ball SP, Eisenberg P. Randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Am Heart J 1999; 137:59-71
93. Hochman JS, Wali AU, Gavrila I, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999; 138:313-318
94. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292:89-96
95. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26:313-318
96. FRISC Study Group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347:561-568
97. Klein W, Buchwald A, Hillis SE, et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96:61-68
98. Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447-452
99. Antman E. Enoxaparin prevents death and cardiac ischemic events in unstable angina, non-Q wave MI: results of the TIMI 11B Trial. Circulation 1999; 100:1593-1601
100. FRAX. I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6 day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX. I.S. Eur Heart J 1999; 20: 1553-1562
101. FRISC II Investigators. Prolonged low molecular mass haparin (dalteparin) in unstable coronary artery disease: a prospective randomized multicenter trial. Lancet 1999; 354: 701-707
102. Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003; 146:304-310
103. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292:55-64
104. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:4.5-54
105. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter trial. Lancet 1999; 354:708-715
106. Cohen M, Théroux P, Borzak S, et al. On behalf of the ACUTE II Investigators: randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II Study. Am Heart J 2002; 144:470-477
107. James S, Armstrong P, Califf R, et al. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J 2002; 23:1538-1545
108. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glucoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107:238-244
109. Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29:1474-1482
110. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001; 103:658-663
111. Choussat R, Montalescot G, Collet JP, et al. A unique low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40:1943-1950
112. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003; 41:394-402
113. Von Ginneken CAM, Russel FGM. Saturable pharmacokinetics in the renal excretion of drugs. Clin Pharmacokinet 1989; 16:38-54
114. Becker RC, Spencer FA, Gibson M, et al. Influence of patients characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143:753-759
115. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular weight heparin? Arch Intern Med 2002; 162:2605-2609
116. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the NICE-3 Study. Am Heart J 2003; 146:628-634
117. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002; 144:615-624
118. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84:1391-1395
119. Grines CL. Anticoagulation requirements for coronary interventions and the role of low molecular weight heparins. J Invasive Cardiol 1999; 11(suppl A):7A-12A
120. Brieger D, Solanki V, Gaynor M, et al. Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes. Am J Cardiol 2002; 89:1167-1170
121. Arjomand H, Surabhi SK, Cohen M. Unfractionated versus fractionated heparin for percutaneous coronary intervention. Curr Cardiol Rep 2002; 4:327-333
122. Preisack MB, Bonan R, Meisner C, et al. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty: a comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial). Eur Heart J 1998; 19:1232-1238
123. Miller L, Gupta A, Bertolet BD. Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the sitting of early percutaneous coronary intervention for acute coronary syndromes. J Invasive Cardiol 2002; 14:247-250
124. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41:20-25
125. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001; 141:348-352
126. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355:1006-1017
127. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994; 90:908-914
128. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study; fraxiparine Angioplastie Coronaire Transluminale. Circulation 1997; 96:3396-3402
129. Amann FW, Neuenschwander C, Meyer BJ. Fraxiparin for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Haemost 1993; 1:160-163
130. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial; efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998; 97:1702-1707
131. Simoons ML, Bobbink IW, Boland J, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004; 43:2183-2190
132. Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005; 111:1390-1397
133. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464-1476
134. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359:294-302
135. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997; 96:769-777
136. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353:429-438
137. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999; 100:2049-2053
138. Bittl JA, S Trony J, Blinker JA, et al. For the Hirulog Angioplasty Study
139. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004; 93:1092-1096
140. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863
141. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial; the Thrombolysis in Myocardial Infarction. Am Heart J 2002; 143:229-234
142. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203-2216
143. Ottervanger JP, Armstrong P, Baruathan ES, et al. Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome: a report from GUSTO IV-ACS. Eur Heart J 2004; 25:1494-1501
144. Lenderink T, Boersma E, Ruzyllo W, et al. Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. Am Heart J 2004; 147:865-873
145. James SK, Siegbahn A, Armstrong P, et al. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. Am Heart J 2004; 147:267-274
146. Merlini PA, Repetto A, Lombardi A, et al. Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy. Circulation 2002; 105:928-932
147. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999; 99: 2892-2900
148. Kleiman NS, Lincoff AM, Flaker GC, al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 2000; 101:751-757
149. Kleiman NS, Tracy RP, Talley JD, et al. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2000; 9:5-12
150. Ronner E, Boersma E, Laarman GJ, et al. Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial; Platelet Glycoprotein IIB/IIIA in Unstable Angina: Receptor Suppression Using Integrilin Therapy. J Am Coll Cardiol 2002; 39:1924-1929
151. Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrum Therapy (PURSUIT) trial. Circulation 2002; 105:322-327
152. Labinaz M, Kaul P, Harrington RA, et al. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: results from the PURSUIT trial. Can J Cardiol 2004; 20:773-778
153. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet 2002; 360:342-343
154. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina: the PARAGON Investigators; Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998; 97:2386-2395
155. Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study: the PARAGON B International Steering Committee. Am Heart J 2000; 139:563-566
156. Huynh T, Theroux P, Snapinn S, et al. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Am Heart J 2003; 146:668-673
157. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23:223-229
158. de Lemos JA, Blazing MA, Wiviott SD, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J 2004; 25:1688-1694
159. Fitchett DH, Langer A, Armstrong PW, et al. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide: long-term results of the Integrum and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J 2006; 151:373-379
160. Mahaffey KW, Cohen M, Garg J, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and i year in the SYNERGY trial, JAMA 2005; 294:2594-2600
161. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45-54
162. Montalescot G, Bal-dit-Sollier C, Chibedi D, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 2003; 91:925-930
163. Roe MT, Christenson RH, Ohman EM, et al. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J 2003; 146:993-998